About Us
MacroGene AI Private Limited was founded in 2026 with a simple belief at its core: Computing First. We exist to replace trial-and-error discovery with predictive intelligence.
Predictive intelligence for modern therapeutic discovery.
Our work is grounded in more than two decades of real R&D experience supporting discovery programs at Aragen Life Sciences, Zydus Lifesciences, and Sun Pharma Advanced Research Company Limited.
From humanization and epitope mapping to computational point-mutation studies that guided an antibody toward successful ADC development, this experience forms the scientific backbone of MacroGene AI.
Today, we operate as a hybrid platform-plus-services company with a strong emphasis on high-value computational services across biologics and chemistry.
Our Team
Experienced computational scientists, chemists, and operations leaders driving cross-disciplinary drug discovery and platform development.
Sairam Kalapatapu
Founder-Director
Brings 22 years of industry experience in computer-aided drug design and computational modelling across small molecules, biologics, and oligonucleotides. Career spans leading R&D organizations including Aragen Life Sciences, Zydus Lifesciences, and Sun Pharma Advanced Research Company Limited. Expert in hit identification, lead optimization, antibody humanization, epitope mapping, and mechanistic modelling. Authored 21 peer-reviewed publications and inventor on 6 patents. Serves on the Board of Directors at Anveta Therapeutics and scientific consultant to Anveta Therapeutics and OmGene Lifesciences.
Chetan Puri
Computational Chemist & Synthetic Chemistry Advisor
Chetan Puri is a gold medalist in synthetic organic chemistry and a computational chemist with deep expertise in molecular modelling, small‑molecule design, and advanced chemical synthesis. He evolved from hands‑on synthetic chemistry to leading computational workflows, contributing to discovery programs through docking, virtual screening, molecular dynamics, and homology modelling. He collaborates effectively across multidisciplinary scientific teams, bringing clarity, precision, and strong scientific judgment to discovery programs. Chetan also brings operational and infrastructure strengths through Red Hat System Administration certification and experience managing Linux‑based servers, enabling efficient handling of computational pipelines and modelling environments.
Supriya Pradhan
Computational Chemist & Synthetic Chemistry Advisor
Supriya Pradhan is a computational chemist and AI‑driven drug discovery professional with extensive experience across leading pharmaceutical and life sciences organizations. She has worked at the intersection of chemistry, biology, and machine learning, contributing to research programs involving small molecules, peptides, and antibody therapeutics. Her expertise spans molecular modelling, molecular dynamics, protein–ligand docking, free‑energy methods, QSAR and machine‑learning model development, and AI‑enabled predictive systems for modern drug discovery. With a strong foundation in both synthetic and computational chemistry, Supriya has also contributed to next‑generation cheminformatics solutions for predictive retrosynthesis and reaction‑condition optimization. She brings scientific depth, innovation‑driven thinking, and practical execution to multidisciplinary teams, helping build scalable AI‑powered solutions for contemporary biotech and healthcare research.
Vijayalakshmi Vadlamannati
Head- Finance & Business Development
Vijayalakshmi Vadlamannati is a finance and accounting professional with a strong analytical foundation built on a Master of Commerce, an MBA in Finance, and an Advanced Diploma in Mathematics from Osmania University. She brings disciplined financial judgment across budgeting, cost control, audit coordination, and financial planning, supported by deep numerical rigor and a structured, methodical working style. She also has extensive experience teaching commerce and mathematics in India and East Africa, strengthening her clarity in communication and ability to simplify complex financial concepts. She combines financial acumen, mathematical rigor, and a calm, structured working style suited for finance‑controller responsibilities.
Our clients include biotech startups, mid-to-large pharma teams, academic groups, and investors seeking mechanistic clarity. We speak the language of science, but with a commercial awareness of timelines, risk, and decision-making. Whether it’s identifying a membrane-proximal epitope that avoids a secreted receptor fragment, predicting developability issues before they surface, or ranking variants for experimental validation, our goal is always the same: deliver insights that accelerate real-world progress.
